SCNX — Scienture Holdings, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1382574 ·
Last close
$3.76
Market Cap
$154.40M
52W High
$65.00
52W Low
$3.23
ADV30
285,870
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 343,639 335,779 -2,699,733 -2,822,371 87,734,007 8,188,140 23,632,481
Mar 2026 56,325 53,850 -3,509,499 -3,402,264 80,661,705 3,542,754 13,841,265
Dec 2025 -168,699 -243,812 -3,154,363 -28,120,333 84,178,330 6,662,008 14,057,946
Sep 2025 590,050 574,621 -4,361,206 -3,607,361 104,830,290 355,692 22,160,659

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,345,280
Investing CF
$0
Financing CF
$14,835,596
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-83,953,501
Inventory
$210,934
Receivables
$722,545
ST Investments
—
EBIT TTM
$-40,395,968
Pretax Income TTM
$-43,845,409
Interest Exp TTM
$3,449,441
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$821,315
EBITDA
$-12,361,262
Free Cash Flow
$-7,611,433
Enterprise Value
$16,787,558
Total Cash
$8,188,140
Total Debt
$10,689,481
Shares Out
41,064,146
Trailing EPS
$-2.03
Book Value
$1.56
ROE
-53.5%
ROA
-8.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 431,609 -16,244,792 -41,512,264 84,178,330 14,057,946 70,120,384 -13,379,683
Dec 2024 136,643 -14,701,015 9,065,798 104,853,805 25,781,684 79,072,121 -14,265,238
Dec 2023 1,363,830 -4,396,451 -17,843,574 12,532,913 11,990,560 542,353 -2,225,192
Dec 2022 10,250,168 -2,040,719 -3,472,099 3,710,026 3,367,159 763,136 -1,564,668
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$477,676
NetIncome TTM
$-41,850,531
OpCashFlow TTM
—
Assets (Latest)
$80,661,705
Forward EPS
$0.00

Peers — same industry

TickerNameMarket CapLastDaily %
MENS Jyong Biotech Ltd. $155.89M $2.10 —
NERV Minerva Neurosciences, Inc. $151.84M $3.18 —
TLSA Tiziana Life Sciences Ltd $151.44M $1.19 —
MSLE Satellos Bioscience Inc. $158.91M $7.49 —
KRRO Korro Bio, Inc. $149.61M $10.16 —

News headlines (Yahoo Finance, 1h cache)

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
2026-10-02 12:05 · Yahoo
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
2026-10-02 11:46 · Yahoo
Scienture Holdings, Inc. Announces Reverse Stock Split
2026-09-30 20:05 · Yahoo
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
2026-09-22 12:15 · Yahoo
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
2026-06-18 12:05 · Yahoo
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
2026-06-09 11:46 · Yahoo
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
2026-06-02 12:05 · Yahoo
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
2026-05-18 12:38 · Yahoo
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
2026-04-06 12:05 · Yahoo
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
2026-05-06 12:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.